Geographic variation of decipher genomic classifier in patients with early prostate cancer.

Authors

null

Daniel Keizman

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Daniel Keizman , Elai Davicioni , Avivit Peer , Hadas Dresler , Avishay Sella , David Leonid Sarid , Keren Rouvinov , Yoav Manaster

Organizations

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Veracyte, Inc, San Diego, CA, Rambam Medical Center, Haifa, Israel, Shaare Zedek Medical Center, Jerusalem, Israel, Sourasky Medical Center, Tel Aviv, Israel, Ichilov Hospital, Sourasky Medical Center, Tel Aviv-Yafo, Israel, Soroka Medical Center, Beer Shech, Israel, Progenetics IL, Azur, Israel

Research Funding

No funding received
None.

Background: External factors such as environmental or lifestyle-related exposure may influence genomic composition of cancer, and therefore its progression and outcome. Thus geographic data is of importance. Decipher is a gene expression classifier used in risk stratification of early non metastatic prostate cancer. Currently, there are no data reporting geographic variation of the test. We aimed to analyze Decipher genomic score results among Israeli patients, in comparison to American patients. Methods: The Decioher database (Decipher Biosciences Inc) contains data from patients who have given consent for broad data-sharing. We identified and analyzed Decipher test results ordered among Israeli patients with localized prostate cancer. Matched analysis to the US population was done. Results: 144 patients (median age 69.5, range 64-74) were included in the present analysis. The clinical NCCN risk grouping was low in 42.4% (n=61), favorable intermediate in 38.9% (n=56), unfavorable intermediate in 17.4% (n=25), and high risk in 1.4% (n=2). Physicians primarily obtained Decipher for low-intermediate NCCN risk. Median Decipher score was 0.57 (Q1 0.385, Q3 0.823). Decipher risk grouping was low in 38.1% (n=61), intermediate in 16.9% (n=27), and high in 45% (n=72). Median Decipher score increased with Grade Group. 46% of NCCN low risk patients had a higher risk as per Decipher. 82% of NCCN favorable intermediate and unfavorable intermediate risk were reclassified to lower or higher risk. 9% of NCCN high risk patients had a lower risk as per Decipher. The present study cohort had a higher proportion of higher Decipher scores than observed in similar grade US population (n=43065) in the Decipher database (Median 0.43, Q1 0.27, Q3 0.66; 52%/18%/30% with low/intermediate/high risk). Conclusions: The preliminary results of the present study suggest a higher proportion of high risk Decipher among Israeli patients with early prostate cancer. These results should be interpreted cautiously. The study and further data collection are ongoing.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 376)

DOI

10.1200/JCO.2023.41.6_suppl.376

Abstract #

376

Poster Bd #

N14

Abstract Disclosures

Similar Abstracts